GLP-1 medications for weight loss, including Wegovy® (semaglutide) and Zepbound® (tirzepatide), can affect hunger, fullness, food intake, and digestion. This Rehealthify explainer covers common GLP-1 side effects, important safety information, how these medications are taken, how they work inside the body, and how they may fit into a long-term weight-management plan. Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, which acts on both GIP and GLP-1 receptors. While both are FDA-approved for chronic weight management in certain patients, their dosing, instructions, and indications are not identical. Chapters 00:00 Introduction 00:10 Why It’s Prescribed 00:34 Side Effects & Safety 01:39 How to Take It 02:01 How It Works 02:29 Treatment Support 02:48 The Big Picture For more clear, evidence-based health information without the hype, subscribe to Rehealthify. Medical Disclaimer: This content is for educational and informational purposes only and is not medical advice. Always consult a qualified healthcare professional regarding your health, medications, and treatment decisions. Do not start, stop, or adjust a medication based solely on this video. Sources & References Wegovy® (semaglutide) — U.S. Prescribing Information, Novo Nordisk https://www.novo-pi.com/wegovy.pdf Zepbound® (tirzepatide) — U.S. Prescribing Information, Eli Lilly and Company https://pi.lilly.com/us/zepbound-uspi.pdf National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — Prescription Medications to Treat Overweight & Obesity https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity U.S. Food and Drug Administration — Zepbound Approval for Chronic Weight Management https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management #glp1 #weightlossmedications #wegovy #zepbound #semaglutide #tirzepatide